Capecitabine and lapatinib for the first‐line treatment of metastatic/recurrent head and neck squamous cell carcinoma

• Published in: Cancer Vol. 122; no. 15; pp. 2350 - 2355
• Main Authors: Weiss, Jared M., Bagley, Stephen, Hwang, Wei‐Ting, Bauml, Joshua, Olson, Juneko Grilley, Cohen, Roger B., Hayes, David Neil, Langer, Corey
• Format: Journal Article
• Language: English
• Published: United States 01.08.2016
• Subjects: Aged; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; capecitabine; Capecitabine - administration & dosage; Carcinoma, Squamous Cell - drug therapy; Carcinoma, Squamous Cell - mortality; Carcinoma, Squamous Cell - pathology; Female; head and neck neoplasms; Head and Neck Neoplasms - drug therapy; Head and Neck Neoplasms - mortality; Head and Neck Neoplasms - pathology; Humans; Lapatinib; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Quinazolines - administration & dosage; Retreatment; Squamous Cell Carcinoma of Head and Neck; survival; toxicity; Treatment Outcome; head and neck neoplasms; toxicity; lapatinib; capecitabine; survival

BACKGROUND The combination of cisplatin, 5‐fluorouracil, and cetuximab is a standard treatment for patients with recurrent/metastatic head and neck cancer, with a high rate of toxicity. Identifying less toxic, equally effective regimens is imperative. Therefore, in the current study, the authors inv...